Background. Nitric oxide inhibits platelet adhesion and platelet aggregation in vivo. In this study, we investigated the effects of the nitric oxide donor SIN-1 on platelet adhesion and platelet-thrombus formation following experimental angioplasty.
SIN-1 Reduces Platelet Adhesion and Platelet
Thrombus Formation in a Porcine Model of Balloon Angioplast Angioscopic1'2 and histological3-5 studies have provided insight into the morphological changes that accompany balloon angioplasty. The procedure inevitably leads to endothelial denudation, and atheromatous plaque rupture also may result in intimal flap formation and medial dissection.1-5 The loss of vascular integrity acts as a potent stimulus to coagulation and to the activation of circulating platelets.6 Fresh platelet thrombus is therefore found in the majority of cases at the site of angioplasty injury. 1, 2 The adhesion of platelets to the exposed subendothelium is the first event in the thrombotic process.7
Experimental models of balloon angioplasty have demonstrated that the extent of subsequent thrombosis is related to the severity and depth of vascular injury6 '8 and to the distribution of shear stress around the site of injury.9 Therefore, the deeper the injury6,8 and the more severe the residual stenosis,10'11 the greater is the thrombotic response following angioplasty. Balloon dilatation most often leads to deep intimal and medial rupture, exposing circulating blood to highly thrombogenic fibrillar collagen and tissue thromboplastins12'13 and resulting in local platelet aggregation and thrombus formation.6'14-16 If superficial intimal injury alone occurs and the internal elastic lamina remains intact, the stimulus to thrombosis is less, and platelet deposition is usually restricted to that of an adherent monolayer.6'14 '15 The nature of the thrombotic response and the extent of acute platelet deposition are important factors in determining the outcome following angioplasty. 17 Platelet adhesion is followed by degranulation, with the local release of substances that encourage platelet aggregation and vasoconstriction.7 Excessive platelet aggregation and thrombus formation contribute to acute vessel closure, which occurs in 2-12% of cases,17 and the administration of antiplatelet therapy has reduced the incidence of this complication of angioplasty. 18, 19 Furthermore, the release of platelet-derived growth factors, which promote smooth muscle cell proliferation and migration within the injured vessel wall, [20] [21] [22] has been implicated in the pathogenesis of intimal hyperplasia,2324 which, when excessive, underlies the development of restenosis following angioplasty. [25] [26] [27] platelets are likely to be the main source of plateletderived growth factors following vessel wall injury. 28 Although some antiplatelet29 and antithrombin agents15'16'29'30 have reduced platelet aggregation and therefore platelet thrombus formation following experimental angioplasty, none have proved effective in achieving this while inhibiting platelet adhesion at the site of balloon dilatation. 1-5'1629,30 Endothelium-derived nitric oxide plays an important role in modulating platelet function. 31 The stimulated release of nitric oxide inhibits platelet adhesion to cultured endothelial cells in vitro32'33 and reduces platelet aggregation in vivo.31 Nitric oxide may therefore play an important role in determining the "nonadhesive" properties of vascular endothelium. After angioplasty, the loss of endothelium at the site of balloon injury promotes local platelet activation through the exposure of subendothelial structures7 and probably also through the cessation of local nitric oxide production. Nitrovasodilators serve as an exogenous source of nitric oxide34 and possess both antiaggregatory31 and antiadhesive35 properties when administered in vivo. This study was performed to investigate whether the administration of the nitrovasodilator SIN-1, which liberates nitric oxide spontaneously,36 inhibits platelet thrombus formation following carotid angioplasty in the pig and whether this occurs in association with inhibition of platelet adhesion at the angioplasty site.
Methods
The study was performed using 20 Large White pigs aged 3-4 months with a mean weight of 33.8±1.9 kg. Pigs were sedated with ketamine (750 mg i.m.), and anesthesia was induced by inhalation of 0.5% halothane and maintained by the continuous intravenous infusion of fentanyl (0.01 mg/ml), etomidate (0.04 mg/ml), and ketamine (1 mg/ml) into the marginal ear vein. The animals were mechanically ventilated, and continuous ECG monitoring was performed throughout the procedure. After surgical exposure, a 9F sheath was inserted into the right femoral artery, and arterial blood pressure was monitored thereafter through its sidearm. All experiments were performed according to the British Home Office guidelines on animal experimentation.
Experimental Protocol
Sixteen pigs were randomized to receive an intravenous infusion of either SIN-1 (10 ,ug/kg/min, n=8) or placebo (normal saline, n=8), which was begun 1 hour before angioplasty and continued until the time of sacrifice. Preliminary experiments in four pigs had revealed that this dose of SIN-1 led to a mean reduction in systolic blood pressure of 30%. The extent of plateletvessel wall interaction is partly determined by local shear rate,9 which will be influenced by changes in blood pressure and vessel diameter. Therefore, to document the effect of a decrease in systolic blood pressure secondary to vasodilatation per se on platelet deposition after angioplasty, an additional control group of animals (n=4) was studied in which controlled hypotension was initiated 1 hour before angioplasty and continued until the time of sacrifice. In these animals, trimetaphan was administered as a continuous intravenous infusion at a dose that was titrated against systolic blood pressure. Trimetaphan is a ganglion-blocking agent that produces hypotension due to vasodilatation37 but has no documented direct effects on platelet function. In addition, all animals (n=20) received a bolus of heparin (50 units/kg) when treatment began with SIN-1, placebo, or trimetaphan, which was followed by an intravenous infusion at a dose of 50 units/kg/hr. Arterial blood pressure and heart rate were recorded at baseline and again immediately before angioplasty.
Angioplasty was begun exactly 60 minutes after initiating treatment with SIN-1, trimetaphan, or placebo and was performed using an 8F 8-mm Meditech balloon catheter. The catheter was advanced under fluoroscopic control into the left carotid artery and positioned at a level between cervical vertebrae 1 and 3. The balloon was inflated to 6 atm for a duration of 30 seconds on five separate occasions, with an interval of 60 seconds between each inflation. At the end of the fifth inflation, the balloon catheter was pulled back into the common carotid artery and then advanced without delay into the right carotid artery. The dilatation protocol was repeated at a level in this artery similar to that of the left carotid angioplasty. The total duration of the angioplasty procedure was 16-18 minutes in all experiments with the interval between left and right carotid dilatations kept to a minimum (1-3 minutes). Fifteen minutes after the last inflation, 100 ml of 0.5% Evans blue dye in 0.9% saline was injected into the ascending aorta to demarcate areas of endothelial damage. 38 The animal was then administered an overdose of pentobarbital. After desanguination using physiological saline (Kreb's solution), perfusion fixation of the vessels was performed in situ at physiological pressure (100 mm Hg) for 15 minutes using 5 1 of 2% glutaraldehyde and 1% paraformaldehyde solution in sodium phosphate buffer (pH 7.4). The vessels were carefully excised and immersed in the same fixative for an additional 12 hours.
Tissue Analysis
Each artery was cleaned and stripped of adventitia. The area of balloon injury was easily identifiable by the localized intensity of Evans blue staining. Each dilated area was divided into two segments. In addition, a segment of the distal uninjured vessel was taken from each carotid artery to act as a control. The segments were placed in a gamma well counter for quantification of platelet deposition (see below) and later opened longitudinally to inspect for uniformity of Evans blue staining. Two sections were obtained from each segment for histological analysis. In segments where visual inspection revealed an obvious intimal tear, transverse sections were taken at the site of the lesion. In the absence of a macroscopically visible tear, transverse sections were taken at two different sites in the arterial segment from areas where the Evans blue staining was most intense. Histological sections from each site were stained with hematoxylin and eosin and with van Gieson elastic stain. All sections were viewed by two observers who were "blinded" to the treatment regimen. Segmental injury was defined as either superficial (endothelial denudation alone with an intact internal elastic lamina in both sections) or deep (rupture of the internal elastic lamina, with a tear into the media in at least one of the sections). Two or three specimens were randomly selected from each segment and, after coating with carbon and gold-palladium alloy using standard techniques, examined by scanning electron microscopy.
Quantification of Platelet Deposition
Autologous pig platelets were labeled with "1In tropolone using a method that has been previously de-scribed39 and were reinjected 20-24 hours before the procedure. To ensure that the 1"'In had remained attached to platelets, a sample of blood was withdrawn at the time of angioplasty from which platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were prepared. The`11In activity in the samples of PRP and PPP was counted separately in a gamma well counter. The proportion of the total counts that were contained within the PPP was <5% in all experiments, implying that minimal extravasation of`11In had occurred into the plasma. "'In activity on each arterial segment and in three samples of blood drawn immediately before sacrifice was also counted in a gamma well counter. Each sample of blood was weighed using a microbalance, and the volume of each was calculated after weighing 1 ml of blood from the same animal. After the platelet count of each sample was measured (Technicon H-1 system, Bayer Diagnostics), the number of platelets per count per minute was calculated, and the platelet deposition on each arterial segment was thereby determined. The length (1) and diameter (d) of arterial segments were measured using a dial caliper, and the surface area was then calculated as surface area= Hrld. Platelet deposition on each segment was then expressed per square centimeter. The mean platelet deposition on superficially and deeply injured segments was calculated for each animal.
Platelet Studies
Arterial blood was drawn into a syringe containing anticoagulant (1:9, 3.8% trisodium citrate). Samples were taken for ex vivo whole blood aggregometry and for measurement of platelet cyclic GMP (cGMP) and cyclic AMP (cAMP) concentrations at baseline (before SIN-1, placebo, trimetaphan, or heparin therapy) and again 60 minutes after treatment was commenced (see below).
Ex vivo whole blood aggregometry. Impedance whole blood aggregometry was commenced immediately after withdrawal of the blood samples. Arterial blood (0.5 ml) and normal saline (0.5 ml) were placed in a plastic cuvette and incubated at 370C. Aggregometry was measured on pretreatment samples after the addition of a threshold concentration of the agonist ADP (1-Sx 106 M) and was repeated on the posttreatment sample using the same predetermined concentration of agonist. On each occasion, the extent of aggregation was calculated as the increase in electrical impedance from baseline to 5 minutes following the addition of the aggregating agent.
Platelet cGMP and cAMP concentrations. PRP was obtained by centrifugation of arterial blood at 140g for 10 minutes. The platelet count in each sample of PRP was determined. One-milliliter samples of PRP were then centrifuged at 2,500g for an additional minute to obtain a platelet pellet. One milliliter of 6% trichloroacetic acid was added to each platelet pellet and vortexed for 1 minute. Samples were then centrifuged at 9,000g for 15 minutes, and the aqueous phase was stored at -20°C. The cGMP and cAMP contents within the aqueous phase were later assayed using commercially available radioimmunoassay kits (Amersham Int.). For cGMP estimation, 25 ,ul of acetylation reagent (1 vol of acetic anhydride with 2 vol of triethylamine) was added to each 500-,ul sample to increase the sensitivity of the assay, but the methodology (see below) was otherwise similar for the measurement of both cGMP and cAMP. Then, 100 ,ul of rabbit anti-cGMP or anti-cAMP antibody was added to 100 ,ul of sample, and, after vortexing, the mixture was allowed to incubate for 1 hour at room temperature. One hundred microliters of 125Ilabeled cGMP or cAMP was then added to each assay tube and after further mixing was incubated for 3 hours (cAMP) or overnight (cGMP) at 4°C. Antibody-bound cGMP or cAMP was separated by centrifugation for 10 minutes at 1,500g after the addition of 500 ,u of Amerlex-M secondary antibody, which had been bound to polymer particles. The tubes were then inverted, placed on a pad of absorbent tissue for 5 minutes, and firmly blotted. The radioactivity in the remaining pellet was determined by placing each tube in a gamma scintillation counter for 60 seconds. The concentration of unlabeled cGMP or cAMP in each sample was then determined by interpolation from a standard curve and was expressed per 109 platelets.
Bleeding time. The ear bleeding time was measured at baseline and immediately before angioplasty, using a standard technique.40 Briefly, the ear was cleaned, and an incision was made on the posterior surface using a Medipoint blood lancet to a depth of 3 mm, with care taken to avoid superficial veins. The ear was then placed into a beaker of isotonic saline that had been warmed to 37°C. The interval of time was measured between puncture and the cessation of bleeding.
Statistical Analysis
The mean platelet deposition on injured (superficial and/or deep) and on distal uninjured arterial segments was calculated in each animal. These data were then logarithmically transformed since they are of a nonparametric distribution. Because of the influence that the depth of arterial injury exerts on the extent of platelet deposition,6.8 values for superficially and deeply injured segments were analyzed separately. The log mean platelet deposition was compared after treatment with SIN-1 or placebo using an unpaired Student's t test. The log mean platelet deposition after superficial arterial injury was compared among the three groups of animals treated with SIN-1, trimetaphan, or placebo using ANOVA. The significance of differences among the groups was determined using Scheffe's test. Baseline and posttreatment values were compared using a paired Student's t test for parameters that were measured before and after SIN-1, trimetaphan, or placebo administration. Results are expressed as mean±SEM. A difference was considered statistically significant when p<0.05.
Results

Hemodynamic Changes
The data are summarized in Table 1 . Hemodynamic parameters remained stable during placebo experiments. Treatment with SIN-1 led to a significant reduc- tion in systolic and diastolic blood pressures and a significant increase in heart rate. The administration of timetaphan also led to significant changes in systolic blood pressure and heart rate that were comparable to those that followed treatment with SIN-1.
Platelet Deposition
The data are summarized in Figures 1 and 2 . Platelet deposition was significantly greater after deep than after superficial injury in pigs treated with placebo (p<0.005) or SIN-1 (p<0.001) ( Figure 1 ). Histological analysis revealed that deep arterial injury was present in one or more arterial segments in seven of the eight placebotreated animals (88%) and in four of the eight pigs that were treated with SIN-1 (50%). The number of animals in these two groups that had superficial injury in one or more arterial segments were five (63%) and seven (88%), respectively.
The level of platelet deposition following deep injury in placebo-treated animals was consistent with macroscopic platelet thrombus formation (>20 plateletsx 106/ cm2).i1 This was also the case in the one animal treated with trimetaphan in which deep arterial injury occurred (69.436 plateletsx i06/cm2). SIN-1 led to a significant reduction in platelet deposition following deep arterial injury compared with placebo treatment (10.870±2.415 versus 40.326±9.889 plateletsx 106/cm2, p<0.05), implying a reduction in the extent of platelet thrombus formation (Figure 1 ). After superficial arterial injury, the level of platelet deposition in placebo-treated animals was consistent with the formation of an adherent platelet monolayer (Figure 1) . Despite a significant reduction in systolic blood pressure, the level of platelet deposition in animals treated with trimetaphan was similar to that observed following placebo administration. SIN-1, however, led to a significant reduction in platelet deposition compared with both trimetaphan and placebo treatment (2.231±0.333 versus 5.278±0.606 versus 5.022±1.136 plateletsx106/cm2,p<0.001) ( Figure 2 ). Scanning electron microscopy confirmed that platelets were deposited in the form of a monolayer after superficial injury regardless of the treatment regimen. Although the assessment of platelet deposition using scanning electron microscopy is unavoidably qualitative in view of the relatively small areas of artery that can be examined using this technique, the results appeared to confirm that the number of platelets that were adherent to the damaged vessel wall were markedly reduced in SIN-1treated animals compared with placebo ( Figure 3) .
Platelet deposition on uninjured artery was low in the presence of an intact endothelium and was similar in animals treated with SIN-1 or placebo (Figure 1 ).
Platelet Studies
The data are summarized in Table 2 . The bleeding time was normal in all animals at baseline (<3 minutes) and varied little following treatment with either placebo or trimetaphan. SIN-1, however, led to a modest but nonetheless significant prolongation in bleeding time from baseline values.
The hematocrit was comparable at baseline in the three groups of animals treated with placebo, trimetaphan, or SIN-1 (30.2±1.4% versus 31.3±2.6% versus 28.6±1.3%, p=NS), and whole blood aggregometry was therefore performed under similar circumstances. The extent of ex vivo whole blood aggregation in response to the agonist ADP was not influenced by any of the treatment regimens. Platelet cGMP and cAMP concentrations remained unaltered following treatment with either placebo or trimetaphan. After SIN-1 administration, however, there was a significant twofold rise in cGMP concentration with platelet cAMP concentrations remaining unchanged.
Discussion
The results of this study have shown that the administration of SIN-1 leads to a reduction in platelet deposition and, therefore, platelet thrombus formation at the site of deep arterial injury following balloon angioplasty. In addition, the results corroborate our previous findings that exogenous nitric oxide inhibits platelet adhesion in vivo and thereby reduces platelet monolayer formation following endothelial denudation and superficial arterial injury.32 This is the first intervention that has been shown to reduce both platelet adhesion and platelet thrombus formation in this experimental model of angioplasty.15,"6'30 SIN-1 is the active metabolite of the nitrovasodilator molsidomine41 and releases nitric oxide by spontaneous degradation.36 Nitric oxide activates soluble guanylate cyclase, leading to a rise in intracellular levels of cGMP42 and a reduction in intracellular calcium concentration.43 These changes account for the biological actions of nitric oxide, which include the relaxation of vascular smooth muscle and the modulation of platelet function.44 A rise in platelet cGMP concentration and a fall in blood pressure were observed in this study following SIN-1 but not placebo administration, and these data therefore imply that the changes in platelet function that accompanied treatment with SIN-1 were attributable to nitric oxideinduced activation of platelet guanylate cyclase.
SIN-1 reduces arterial and venous tone,45 and a fall in blood pressure was therefore predictable during its administration. In this study, platelet deposition following superficial arterial injury was similar in the groups of animals treated with either trimetaphan or placebo but was significantly lower in those receiving SIN-i. The fall in systolic blood pressure that accompanied the infusion of trimetaphan was similar to that following treatment with SIN-i; we therefore conclude that the observed effects of SIN-1 on platelet deposition following angioplasty were a true reflection of changes in platelet function rather than a consequence of altered hemodynamics within the carotid circulation.
The increase in bleeding time that was observed in this study following treatment with SIN-i was relatively small but nonetheless would also be consistent with a change in platelet function. While the administration of heparin alone may prolong the bleeding time,13 the dose that was used in this study was small and failed to produce such an effect in animals treated with placebo. Furthermore, similar changes in bleeding time have also been reported following the infusion of the nitric oxide donor nitroprus-side46 and following treatment with the organic nitrate nitroglycerin administered either sublingually47 or intravenously. 48 We conclude, therefore, that the change in bleeding time in this study was likely to have been attributable to the effects of nitric oxide released from SIN-i. SIN-i reduced platelet deposition following deep arterial injury, implying that it exhibits antithrombotic as well as antiadhesive properties when administered in vivo. The mechanism by which SIN-i reduces platelet thrombus formation may be complex. Platelet adhesion is the first event in the thrombotic process, but it is rapidly followed by platelet aggregation and thrombus formation in the event of deep arterial injury.6'15'16 SIN-1 reduced platelet adhesion to areas of superficial arterial injury in this study, and it may be that such an effect could have also contributed to a reduction in the extent of subsequent platelet aggregation when deep arterial injury had occurred. However, it is unlikely that this alone would be sufficient to explain the reduction in platelet thrombus formation that was observed in view of the presence of potent non-platelet-derived platelet activators such as thrombin at the site of injury.15"16 Platelet antiaggregatory effects per se have been demonstrated with molsi-domine41 and Both diminish cyclical reductions in blood flow in stenosed canine coronary arteries,49'-0 reflecting an inhibition of platelet thrombus formation in vivo. In the present study, there were no demonstrable changes in impedance aggregometry following SIN-i administration. Ex vivo whole blood aggregometry, however, does not always accurately reflect events in the whole animal,51 and the findings do not, therefore, eliminate the possibility of an antiaggregatory effect of this dose of SIN-i in vivo. An additional mechanism by which SIN-i may have reduced platelet thrombus formation is through its potential ability to enhance endogenous fibrinolysis.52'-3 Fibrinolysis is mainly regulated by the release from endothelium of tissue-type plasminogen activator (t-PA) and by its inactivation by the plasminogen activator inhibitor type-1 (PAI-1). The administration of molsidomine leads to an increase in plasma t-PA activity and a reduction in PAI-1 activity in humans,54 and these effects are likely to account for the reduction in euglobulin lysis time that has also been observed with molsidomine. 52 Lidbury et al55 showed that the nitric oxide donor sodium nitroprusside also increased plasma t-PA activity and suggested that this fibrinolytic activity may be due to an inhibition of PAMrelease from platelets. Such effects of exogenous nitric oxide on PAI-1 Circulation Vol 87, No 2 February 1993 release from activated platelets have since been confirmed with SIN-153 and therefore are likely to account for the fibrinolytic activity of the nitric oxide donors and to have contributed to the reduction in the extent of platelet thrombus deposition that was observed with SIN-i in this study.
The importance of the results in the present study relate to the unique ability of SIN-i, through the release of nitric oxide, to coincidentally inhibit both platelet adhesion and platelet thrombus formation in vivo. In a similar experimental model of angioplasty, thrombininhibitor therapy, including hirudin and high-dose heparin,1516 and platelet-inhibitor therapy, including low-dose aspirin alone and high-dose aspirin in combination with dipyridamole,29 reduced platelet deposition following deep arterial injury. In none of these studies, however, was platelet adhesion reduced at the site of superficial arterial injury. 15, 16, 29 The organic nitrate nitroglycerin also reduced platelet deposition and vasoconstriction after deep arterial injury, but unlike SIN-1 did not appear to exert any effects on platelet adhesion.56 Although nitric oxide is the active moiety of both SIN-i and nitroglycerin, this apparent discrepancy may be explained by the relative potency of these two agents as platelet inhibitors at the doses that were used in the two studies. The antiplatelet effects of organic nitrates are related to hemodynamic responsiveness57,58 with the most profound effects on platelet function being exhibited in subjects who experience the greatest hemodynamic changes.58 Lam et al56 administered nitroglycerin before angioplasty at a dose that led to only a modest fall in mean arterial blood pressure (9%). They do not comment on the effects of nitroglycerin at this dose on tests of platelet function or platelet cGMP concentration. 56 Folts et a157 found negligible antiplatelet effects of nitroglycerin at a dose (5 gg/kg/min) that reduced mean arterial pressure by 9% from baseline in the dog. At higher doses (10-15 ,ug/kg/min), which led to more profound effects on hemodynamics, however, they describe a significant reduction in cyclical flow variations in stenosed canine coronary arteries, which they attribute to diminished platelet thrombus formation.57 The dose of SIN-i that was used in the present study led to a 29% reduction in systolic blood pressure that was accompanied by a significant rise in platelet cGMP concentration.
It may well be, therefore, that the in vivo plateletinhibitory effects of the nitric oxide donors will become fully apparent only when they are administered at a higher concentration.
The ability of SIN-i to inhibit both platelet adhesion and platelet thrombus formation following vascular injury implies that the use of a nitric oxide donor may be an effective means of modifying both the acute and chronic complications of balloon angioplasty. Other antiplatelet agents that have reduced platelet aggregation and therefore platelet thrombus formation alone have reduced the incidence of acute complications18'19 but have failed to influence the rate of restenosis following angioplasty. 18'19'59 This may be due partly to the inability of these agents to influence platelet adhesion at the site of balloon injury, which alone is sufficient for the local release of platelet-derived growth factors.28W60 The combined antithrombotic and antiadhesive effects of SIN-i therefore imply a theoretical advantage over and above other agents with regard to the way in which platelet behavior may be influenced following angioplasty. The recent discovery that a rise in intracellular levels of cGMP in vascular smooth muscle reduces their proliferation in vitro61,62 provides additional grounds on which to hypothesize that chronic treatment with a nitric oxide donor devoid of the problems of tolerance may influence the behavior of both platelets and smooth muscle cells following vascular injury. Although this at present remains speculative, the results of the present study suggest that the acute and chronic uses of nitric oxide donors in the context of balloon angioplasty require further investigation.
